215,198 Shares in Nuvation Bio Inc. (NYSE:NUVB) Bought by Susquehanna Fundamental Investments LLC

Susquehanna Fundamental Investments LLC acquired a new stake in shares of Nuvation Bio Inc. (NYSE:NUVB) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 215,198 shares of the company’s stock, valued at approximately $572,000.

A number of other institutional investors and hedge funds also recently made changes to their positions in the stock. FMR LLC raised its stake in Nuvation Bio by 54.9% during the 4th quarter. FMR LLC now owns 45,285,572 shares of the company’s stock worth $120,460,000 after buying an additional 16,046,701 shares during the period. Vanguard Group Inc. raised its position in shares of Nuvation Bio by 45.4% during the fourth quarter. Vanguard Group Inc. now owns 15,732,567 shares of the company’s stock worth $41,849,000 after purchasing an additional 4,913,820 shares during the period. Geode Capital Management LLC lifted its holdings in shares of Nuvation Bio by 22.9% in the 4th quarter. Geode Capital Management LLC now owns 4,951,195 shares of the company’s stock worth $13,174,000 after purchasing an additional 922,503 shares in the last quarter. Charles Schwab Investment Management Inc. grew its position in Nuvation Bio by 39.6% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,945,983 shares of the company’s stock valued at $5,176,000 after purchasing an additional 551,968 shares during the period. Finally, Wellington Management Group LLP increased its stake in Nuvation Bio by 8.3% during the 4th quarter. Wellington Management Group LLP now owns 676,024 shares of the company’s stock valued at $1,798,000 after purchasing an additional 52,051 shares in the last quarter. Institutional investors own 61.67% of the company’s stock.

Nuvation Bio Price Performance

Shares of NYSE:NUVB opened at $2.46 on Friday. Nuvation Bio Inc. has a 1 year low of $1.54 and a 1 year high of $3.97. The company has a market capitalization of $833.15 million, a PE ratio of -1.13 and a beta of 1.47. The business has a fifty day moving average price of $1.96 and a two-hundred day moving average price of $2.37.

Insider Activity at Nuvation Bio

In related news, CEO David Hung acquired 300,000 shares of the stock in a transaction on Monday, April 7th. The shares were acquired at an average price of $1.62 per share, with a total value of $486,000.00. Following the completion of the transaction, the chief executive officer now owns 58,781,054 shares in the company, valued at approximately $95,225,307.48. The trade was a 0.51 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. 29.93% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on the stock. Jones Trading assumed coverage on shares of Nuvation Bio in a research note on Wednesday, March 12th. They issued a “buy” rating and a $10.00 price objective on the stock. Citigroup initiated coverage on Nuvation Bio in a research note on Wednesday, April 23rd. They set an “outperform” rating for the company. JMP Securities initiated coverage on Nuvation Bio in a report on Wednesday, April 23rd. They set a “market outperform” rating and a $6.00 price objective for the company. Royal Bank of Canada reaffirmed an “outperform” rating and set a $10.00 target price (up previously from $6.00) on shares of Nuvation Bio in a research report on Tuesday, January 7th. Finally, Wedbush reissued an “outperform” rating and issued a $5.00 price target on shares of Nuvation Bio in a research report on Thursday, March 27th. Five analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $7.83.

Nuvation Bio Profile

Nuvation Bio Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer.